1
|
Wu Y, Arroyo-Currás N. Nucleic Acid-based Electrochemical Sensors Facilitate the Study of DNA Binding by Platinum (II)-based Antineoplastics. Angew Chem Int Ed Engl 2024; 63:e202312402. [PMID: 38227790 PMCID: PMC10939885 DOI: 10.1002/anie.202312402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2023] [Revised: 01/15/2024] [Accepted: 01/16/2024] [Indexed: 01/18/2024]
Abstract
DNA crosslinking agents such as cisplatin and related platinum(II) analogs are effective drugs to treat solid tumors. However, these therapeutics can cause high toxicity in the body, and tumors can develop resistance to them. To develop less toxic and more effective DNA crosslinkers, medicinal chemists have focused on tuning the ligands in square planar platinum(II) complexes to modulate their bioavailability, targeted cell penetration, and DNA binding rates. Unfortunately, linking in vitro DNA binding capacity of DNA crosslinkers with their in vivo efficacy has proven challenging. Here we report an electrochemical biosensor strategy that allows the study of platinum(II)-DNA binding in real time. Our biosensors contain a purine-rich deoxynucleotide sequence, T6 (AG)10 , modified with a 5' hexylthiol linker for easy self-assembly onto gold electrodes. The 3' terminus is functionalized with the redox reporter methylene blue. Electron transfer from methylene blue to the sensor is a function of platinum(II) compound concentration and reaction time. Using these biosensors, we resolve DNA binding mechanisms including monovalent and bivalent binding, as well as base stacking. Our approach can measure DNA binding kinetics in buffers and in 50 % serum, offering a single-step, real-time approach to screen therapeutic compounds during drug development.
Collapse
Affiliation(s)
- Yao Wu
- Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205 (United States)
| | - Netzahualcóyotl Arroyo-Currás
- Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205 (United States)
| |
Collapse
|
2
|
Aher S, Zhu J, Bhagat P, Borse L, Liu X. Pt(IV) Complexes in the Search for Novel Platinum Prodrugs with Promising Activity. Top Curr Chem (Cham) 2024; 382:6. [PMID: 38400859 DOI: 10.1007/s41061-023-00448-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2023] [Accepted: 11/15/2023] [Indexed: 02/26/2024]
Abstract
The kinetically inert, six coordinated, octahedral Pt(IV) complexes are termed dual-, triple-, or multi-action prodrugs based on the nature of the axially substituted ligands. These ligands are either inert or biologically active, where the nature of these axial ligands provides additional stability, synergistic biological activity or cell-targeting ability. There are many literature reports from each of these classes, mentioning the varied nature of these axial ligands. The ligands comprise drug molecules such as chlorambucil, doxorubicin, valproic acid, ethacrynic acid, biologically active chalcone, coumarin, combretastatin, non-steroidal anti-inflammatory drugs (NSAIDs) and many more, potentiating the anti-proliferative profile or reducing the side effects associated with cisplatin therapy. The targeting and non-targeting nature of these moieties exert additive or synergistic effects on the anti-cancer activity of Pt(II) moieties. Herein, we discuss the effects of these axially oriented ligands and the changes in the non-leaving am(m)ine groups and in the leaving groups on the biological activity. In this review, we have presented the latest developments in the field of Pt(IV) complexes that display promising activity with a reduced resistance profile. We have discussed the structure activity relationship (SAR) and the effects of the ligands on the biological activity of Pt(IV) complexes with cisplatin, oxaliplatin, carboplatin and the Pt core other than approved drugs. This literature work will help researchers to get an idea about Pt(IV) complexes that have been classified based on the aspects of their biological activity.
Collapse
Affiliation(s)
- Sainath Aher
- K. K. Wagh College of Pharmacy, Nashik, Maharashtra, 422003, India
- Henan International Joint Laboratory of Medicinal Plants Utilization, College of Chemistry and Molecular Sciences, Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University, Kaifeng, 475004, People's Republic of China
| | - Jinhua Zhu
- Henan International Joint Laboratory of Medicinal Plants Utilization, College of Chemistry and Molecular Sciences, Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University, Kaifeng, 475004, People's Republic of China
| | - Pundlik Bhagat
- Department of Chemistry, School of Advanced Sciences, VIT University, Vellore, 632014, India
| | - Laxmikant Borse
- Sandip Institute of Pharmaceutical Sciences, Nashik, Maharashtra, 422213, India
| | - Xiuhua Liu
- Henan International Joint Laboratory of Medicinal Plants Utilization, College of Chemistry and Molecular Sciences, Key Laboratory of Natural Medicine and Immuno-Engineering of Henan Province, Henan University, Kaifeng, 475004, People's Republic of China.
| |
Collapse
|
3
|
Fang G, Zhang A, Zhu L, Wang Q, Sun F, Tang B. Nanocarriers containing platinum compounds for combination chemotherapy. Front Pharmacol 2022; 13:1050928. [DOI: 10.3389/fphar.2022.1050928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2022] [Accepted: 10/25/2022] [Indexed: 11/11/2022] Open
Abstract
Platinum compounds-based drugs are used widely in the clinic for the treatment of many types of cancer. However, serious undesirable side effects and intrinsic or acquired resistance limit their successful clinic use. Nanocarrier-based combination chemotherapy is considered to be an effective strategy to resolve these challenges. This review introduces the recent advance in nanocarriers containing platinum compounds for combination cancer chemotherapy, including liposomes, polymer nanoparticles, polymer micelles, mesoporous silica nanoparticles, carbon nanohors, polymer-caged nanobins, carbon nanotube, nanostructured lipid carriers, solid lipid nanoparticles, and multilayered fiber mats in detail.
Collapse
|
4
|
Yousuf I, Bashir M, Arjmand F, Tabassum S. Advancement of metal compounds as therapeutic and diagnostic metallodrugs: Current frontiers and future perspectives. Coord Chem Rev 2021. [DOI: 10.1016/j.ccr.2021.214104] [Citation(s) in RCA: 42] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
5
|
Poplinger D, Bokan M, Hesin A, Thankarajan E, Tuchinsky H, Gellerman G, Patsenker L. Ratiometric Fluorescence Monitoring of Antibody-Guided Drug Delivery to Cancer Cells. Bioconjug Chem 2021; 32:1641-1651. [PMID: 34115936 DOI: 10.1021/acs.bioconjchem.1c00205] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Ratiometric measurements utilizing two independent fluorescence signals from a dual-dye molecular system help to improve the detection sensitivity and quantification of many analytical, bioanalytical, and pharmaceutical assays, including drug delivery monitoring. Nevertheless, these dual-dye conjugates have never been utilized for ratiometric monitoring of antibody (Ab)-guided targeted drug delivery (TDD). Here, we report for the first time on the new, dual-dye TDD system, Cy5s-Ab-Flu-Aza, comprising the switchable fluorescein-based dye (Flu) linked to the anticancer drug azatoxin (Aza), reference pentamethine cyanine dye (Cy5s), and Her2-specific humanized monoclonal Trastuzumab (Herceptin) antibody. The ability of ratiometric fluorescence monitoring of drug release was demonstrated with this model system in vitro in the example of the human breast cancer SKBR3 cell line overexpressing Her2 receptors. The proposed approach for designing ratiometric, antibody-guided TDD systems, where a "drug-switchable dye" conjugate and a reference dye are independently linked to an antibody, can be expanded to other drugs, dyes, and antibodies. Replacement of the green-emitting dye Flu, which was found not detectable in vivo, with a longer-wavelength (red or near-IR) switchable fluorophore should enable quantification of drug release in the body.
Collapse
Affiliation(s)
- Dvir Poplinger
- Department of Chemical Sciences, the Faculty of Natural Sciences, Ariel University, Ariel 40700, Israel
| | - Maksym Bokan
- Department of Chemical Sciences, the Faculty of Natural Sciences, Ariel University, Ariel 40700, Israel
| | - Arkadi Hesin
- Department of Molecular Biology, the Faculty of Natural Sciences, Ariel University, Ariel 40700, Israel
| | - Ebaston Thankarajan
- Department of Chemical Sciences, the Faculty of Natural Sciences, Ariel University, Ariel 40700, Israel
| | - Helena Tuchinsky
- Department of Molecular Biology, the Faculty of Natural Sciences, Ariel University, Ariel 40700, Israel
| | - Gary Gellerman
- Department of Chemical Sciences, the Faculty of Natural Sciences, Ariel University, Ariel 40700, Israel
| | - Leonid Patsenker
- Department of Chemical Sciences, the Faculty of Natural Sciences, Ariel University, Ariel 40700, Israel
| |
Collapse
|
6
|
Jia C, Deacon GB, Zhang Y, Gao C. Platinum(IV) antitumor complexes and their nano-drug delivery. Coord Chem Rev 2021. [DOI: 10.1016/j.ccr.2020.213640] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
7
|
Lee VEY, Lim ZC, Chew SL, Ang WH. Strategy for Traceless Codrug Delivery with Platinum(IV) Prodrug Complexes Using Self-Immolative Linkers. Inorg Chem 2021; 60:1823-1831. [DOI: 10.1021/acs.inorgchem.0c03299] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Violet Eng Yee Lee
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543, Singapore
- NUS Graduate School of Integrative Sciences and Engineering, National University of Singapore, 21 Lower Kent Ridge Rd, Singapore 119077, Singapore
| | - Zhi Chiaw Lim
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543, Singapore
| | - Suet Li Chew
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543, Singapore
| | - Wee Han Ang
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543, Singapore
- NUS Graduate School of Integrative Sciences and Engineering, National University of Singapore, 21 Lower Kent Ridge Rd, Singapore 119077, Singapore
| |
Collapse
|
8
|
Deng Z, Wang N, Ai F, Wang Z, Zhu G. Nanomaterial‐mediated platinum drug‐based combinatorial cancer therapy. VIEW 2020. [DOI: 10.1002/viw.20200030] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Affiliation(s)
- Zhiqin Deng
- Department of Chemistry City University of Hong Kong Hong Kong SAR P. R. China
- Shenzhen Research Institute City University of Hong Kong Shenzhen P. R. China
| | - Na Wang
- Department of Chemistry City University of Hong Kong Hong Kong SAR P. R. China
- Shenzhen Research Institute City University of Hong Kong Shenzhen P. R. China
| | - Fujin Ai
- College of Health Science and Environment Engineering Shenzhen Technology University Shenzhen P. R. China
| | - Zhigang Wang
- School of Pharmaceutical Sciences Health Science Center Shenzhen University Shenzhen P. R. China
| | - Guangyu Zhu
- Department of Chemistry City University of Hong Kong Hong Kong SAR P. R. China
- Shenzhen Research Institute City University of Hong Kong Shenzhen P. R. China
| |
Collapse
|
9
|
Xiao X, Oswald JT, Wang T, Zhang W, Li W. Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery. Curr Med Chem 2020; 27:3055-3078. [PMID: 30394206 DOI: 10.2174/0929867325666181105115849] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2018] [Revised: 08/30/2018] [Accepted: 10/30/2018] [Indexed: 12/19/2022]
Abstract
As one of the leading and most important metal-based drugs, platinum-based pharmaceuticals are widely used in the treatment of solid malignancies. Despite significant side effects and acquired drug resistance have limited their clinical applications, platinum has shown strong inhibitory effects for a wide assortment of tumors. Drug delivery systems using emerging technologies such as liposomes, dendrimers, polymers, nanotubes and other nanocompositions, all show promise for the safe delivery of platinum-based compounds. Due to the specificity of nano-formulations; unwanted side-effects and drug resistance can be largely averted. In addition, combinational therapy has been shown to be an effective way to improve the efficacy of platinum based anti-tumor drugs. This review first introduces drug delivery systems used for platinum and combinational therapeutic delivery. Then we highlight some of the recent advances in the field of drug delivery for combinational therapy; specifically progress in leveraging the cytotoxic nature of platinum-based drugs, the combinational effect of other drugs with platinum, while evaluating the drug targeting, side effect reducing and sitespecific nature of nanotechnology-based delivery platforms.
Collapse
Affiliation(s)
- Xiao Xiao
- School of Pharmacy, Jilin Medical University, Jilin, 132013, China
| | - James Trevor Oswald
- School of Nanotechnology Engineering, University Of Waterloo, Waterloo, Canada
| | - Ting Wang
- Department of the Gastrointestinal Surgery, The first Hospital of Jilin University, Changchun, Jilin 130021, China
| | - Weina Zhang
- Common Subjects Department, Shangqiu Medical College, Henan 476100, China
| | - Wenliang Li
- School of Pharmacy, Jilin Medical University, Jilin, 132013, China
| |
Collapse
|
10
|
Babu T, Sarkar A, Karmakar S, Schmidt C, Gibson D. Multiaction Pt(IV) Carbamate Complexes Can Codeliver Pt(II) Drugs and Amine Containing Bioactive Molecules. Inorg Chem 2020; 59:5182-5193. [PMID: 32207294 DOI: 10.1021/acs.inorgchem.0c00445] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Multiaction Pt(IV) prodrugs can overcome resistance associated with the FDA approved Pt(II) drugs like cisplatin. Intracellular reduction of the octahedral Pt(IV) derivatives of cisplatin releases cisplatin and the two axial ligands. When the released axial ligands act synergistically with cisplatin to kill the cancer cells, we have multiaction prodrugs. Most Pt(IV) multiaction prodrugs have bioactive ligands possessing a carboxylate that is conjugated to the Pt(IV) because breaking the Pt(IV)-ligand bond releases the active moiety. As many drugs that act synergistically with cisplatin do not have carboxylates, a major challenge is to prepare multiaction Pt(IV) complexes with drugs that have amino groups or hydroxyl groups such that following reduction, the drugs are released in their active form. Our objective was to prepare multiaction Pt(IV) prodrugs that release bioactive molecules having amino groups. Because we cannot conjugate amino groups to the axial position of Pt(IV), we developed a novel and efficient approach for the synthesis of Pt(IV)-carbamato complexes and demonstrated that following reduction of the Pt(IV), the released carbamates undergo rapid decarboxylation, releasing the free amine, as in the case of the PARP-1 inhibitor 3-aminobenzamide and the amino derivative of the HDAC inhibitor SAHA. Pt(IV)-carbamato complexes are stable in cell culture medium and are reduced by ascorbate. They are reduced slower than their carboxylato and carbonato analogues. We believe that this approach paves the way for preparing novel classes of multiaction Pt(IV) prodrugs with amino containing bioactive molecules that up to now were not accessible.
Collapse
Affiliation(s)
| | | | | | | | - Dan Gibson
- Institute for Drug Research, School of Pharmacy, The Hebrew University, Jerusalem 9112102, Israel
| |
Collapse
|
11
|
Tan MX, Wang ZF, Qin QP, Zou BQ, Liang H. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity. Dalton Trans 2020; 49:1613-1619. [PMID: 31942585 DOI: 10.1039/c9dt04594e] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
We herein designed two new PtIV prodrugs of oxoplatin (cis,cis,cis-[PtCl2(NH3)2(OH)2]), [PtIVCl2(NH3)2(O2C-FA)2] (Pt-2) and [PtIVCl2(NH3)2(O2C-RH)2] (Pt-3), by conjugating with ferulic acid (FA-COOH) and rhein (RH-COOH) which have well-known biological activities. Three other Pt(iv) complexes of [PtIVCl2(NH3)2(O2C-BA)2] (Pt-1), [PtIVCl2(NH3)2(O2C-CA)2] (Pt-4) and [PtIVCl2(NH3)2(O2C-TCA)2] (Pt-5) (where BA-COOH = benzoic acid, CA-COOH = crotonic acid and TCA-COOH = trans-cinnamic acid) were also prepared for the comparative study. Like most PtIV prodrug complexes, the cytotoxicity of Pt-3 containing the biologically active rhein (RH-COOH) ligand against lung carcinoma (A549 and A549/DDP) cells was higher than those of Pt-1, Pt-2, Pt-4, cisplatin and Pt-5. Moreover, the cytotoxicity of Pt-3 in HL-7702 normal cells was lower than those of PtIV derivatives bearing BA-COOH, FA-COOH, TCA-COOH and CA-COOH ligands. The highly efficacious Pt-2 and Pt-3 were found to accumulate strongly in the A549/DDP cells, with the prodrug Pt-3 showing highest levels of penetration into the mitochondria. The prodrug Pt-3 effectively entered the A549/DDP cells and caused mitochondrial damage, significantly greater than Pt-2. In addition, the prodrug Pt-3 exhibited higher antitumor efficacy (inhibition rates (IR) = 67.45%) than Pt-2 (28.12%) and cisplatin (33.05%) in the A549/DDP xenograft mouse model. Thus, the prodrug Pt-3 containing the rhein (RH-COOH) ligand is a promising candidate drug targeting the mitochondria.
Collapse
Affiliation(s)
- Ming-Xiong Tan
- Guangxi Key Lab of Agricultural Resources Chemistry and Biotechnology, College of Chemistry and Food Science, Yulin Normal University, 1303 Jiaoyudong Road, Yulin 537000, PR China.
| | - Zhen-Feng Wang
- Guangxi Key Lab of Agricultural Resources Chemistry and Biotechnology, College of Chemistry and Food Science, Yulin Normal University, 1303 Jiaoyudong Road, Yulin 537000, PR China.
| | - Qi-Pin Qin
- Guangxi Key Lab of Agricultural Resources Chemistry and Biotechnology, College of Chemistry and Food Science, Yulin Normal University, 1303 Jiaoyudong Road, Yulin 537000, PR China. and State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmacy, Guangxi Normal University, 15 Yucai Road, Guilin 541004, PR China.
| | - Bi-Qun Zou
- Department of Chemistry, Guilin Normal College, 9 Feihu Road, Gulin 541001, China.
| | - Hong Liang
- State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources, School of Chemistry and Pharmacy, Guangxi Normal University, 15 Yucai Road, Guilin 541004, PR China.
| |
Collapse
|
12
|
Caballero AB, Cardo L, Claire S, Craig JS, Hodges NJ, Vladyka A, Albrecht T, Rochford LA, Pikramenou Z, Hannon MJ. Assisted delivery of anti-tumour platinum drugs using DNA-coiling gold nanoparticles bearing lumophores and intercalators: towards a new generation of multimodal nanocarriers with enhanced action. Chem Sci 2019; 10:9244-9256. [PMID: 32055309 PMCID: PMC7003971 DOI: 10.1039/c9sc02640a] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2019] [Accepted: 08/05/2019] [Indexed: 12/19/2022] Open
Abstract
New gold and lipoic based nanocarriers for the delivery of platinum(ii) and platinum(iv) drugs are developed, which allow enhanced loading of the drug on the surface of the nanocarriers and release in a pH-dependent fashion, with superior release at lower pHs which are associated with many tumours. The conjugate nanoparticles and their conjugates enter cells rapidly (within 3 hours). They tend to cluster in vesicles and are also observed by light and electron microscopies in the cytoplasm, endoplasmic reticulum and nucleus. We further incorporate aminoanthraquinone units that are both fluorophores and DNA intercalators. This results in nanocarriers that after drug release will remain surface decorated with DNA-binders challenging the conventional design of the nanocarrier as an inert component. The outcome is nanocarriers that themselves have distinctive, remarkable and unusual DNA binding properties being able to bind and wrap DNA (despite their anionic charge) and provide enhanced cytotoxic activity beyond that conferred by the platinum agents they release. DNA coiling is usually associated with polycations which can disrupt cell membranes; anionic nanoparticles that can cause novel and dramatic effects on DNA may have fascinating potential for new approaches to in-cell nucleic acid recognition. Our findings have implications for the understanding and interpretation of the biological activities of nanoparticles used to deliver other DNA-binding drugs including clinical drug doxorubicin and its formulations.
Collapse
Affiliation(s)
- Ana B Caballero
- School of Chemistry , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK . ;
| | - Lucia Cardo
- School of Chemistry , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK . ;
| | - Sunil Claire
- School of Chemistry , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK . ;
| | - James S Craig
- Physical Sciences for Health Centre , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK
| | - Nikolas J Hodges
- School of Biosciences , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK
| | - Anton Vladyka
- School of Chemistry , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK . ;
| | - Tim Albrecht
- School of Chemistry , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK . ;
| | - Luke A Rochford
- School of Chemistry , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK . ;
| | - Zoe Pikramenou
- School of Chemistry , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK . ;
| | - Michael J Hannon
- School of Chemistry , University of Birmingham , Edgbaston , Birmingham B15 2TT , UK . ;
| |
Collapse
|
13
|
Shrestha B, Tang L, Romero G. Nanoparticles‐Mediated Combination Therapies for Cancer Treatment. ADVANCED THERAPEUTICS 2019. [DOI: 10.1002/adtp.201900076] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Binita Shrestha
- Department of Biomedical Engineering University of Texas at San Antonio One UTSA Circle San Antonio TX 78249 USA
| | - Liang Tang
- Department of Biomedical Engineering University of Texas at San Antonio One UTSA Circle San Antonio TX 78249 USA
| | - Gabriela Romero
- Department of Chemical Engineering University of Texas at San Antonio One UTSA Circle San Antonio TX 78249 USA
| |
Collapse
|
14
|
Ravera M, Gabano E, McGlinchey MJ, Osella D. A view on multi-action Pt(IV) antitumor prodrugs. Inorganica Chim Acta 2019. [DOI: 10.1016/j.ica.2019.04.025] [Citation(s) in RCA: 47] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
15
|
Lee VEY, Chin CF, Ang WH. Design and investigation of photoactivatable platinum(iv) prodrug complexes of cisplatin. Dalton Trans 2019; 48:7388-7393. [PMID: 30957798 DOI: 10.1039/c9dt00540d] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Platinum(iv) carboxylate scaffolds have garnered considerable research interest because they can be engineered to function as prodrugs of clinical platinum(ii) anticancer drugs. These platinum(iv) prodrug complexes are stable and tunable, and activated by reduction to release their cytotoxic platinum(ii) cargo. Here we propose new platinum(iv) prodrug complexes designed to release cisplatin via photoreduction upon UV irradiation. The central strategy is to utilise aryl carboxylate ligands on the axial positions of that platinum(iv) scaffold that confer significant UV absorption and would stabilise carboxyl radical formation, thus favouring homolytic Pt-O bond cleavage. We isolated and identified aryl carboxyl radicals via spin-trapping and showed that the photoreduced platinum species mirror cisplatin reactivity toward DNA bases, thereby validating the efficacy of this approach.
Collapse
Affiliation(s)
- Violet Eng Yee Lee
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543. and NUS Graduate School of Integrative Sciences and Engineering, National University of Singapore, 21 Lower Kent Ridge Rd, Singapore 119077
| | - Chee Fei Chin
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543.
| | - Wee Han Ang
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543. and NUS Graduate School of Integrative Sciences and Engineering, National University of Singapore, 21 Lower Kent Ridge Rd, Singapore 119077
| |
Collapse
|
16
|
Near-infrared AIEgens as transformers to enhance tumor treatment efficacy with controllable self-assembled redox-responsive carrier-free nanodrug. Biomaterials 2018; 193:12-21. [PMID: 30550999 DOI: 10.1016/j.biomaterials.2018.12.007] [Citation(s) in RCA: 57] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2018] [Revised: 11/27/2018] [Accepted: 12/08/2018] [Indexed: 12/22/2022]
Abstract
Nanosized drug delivery systems (nDDS) have been extensively exploited to achieve improved therapeutic performance of chemotherapeutic drugs in cancer treatment. Carrier-free nanodrugs have recently emerged as a promising generation of nDDS. In this work, a carrier-free theranostic nanodrug was fabricated by incorporating near-infrared (NIR) emission AIEgens (NPAPF) with redox responsive camptothecin-gemcitabine amphiphilic prodrug (CPT-ss-GEM) to form self-assembled nanoparticles (NCssG NPs). The introducing of AIEgens is designed to not only endow the nDDS with NIR imaging ability but also to act as transformers to modulate the geometry of the self-assembled nanostructures from nanowires to spherical nanoparticles. Interestingly, this unique geometric effect is further demonstrated to be very crucial to the anticancer performance of the nDDS in vitro and in vivo. The AIEgens-doped spherical nanoparticles NCssG NPs showed much higher cellular uptake efficiency and tumor penetration ability, therefor achieving much stronger anticancer efficacy than free CPT/GEM mixture and CPT-ss-GEM nanowires (CssG NWs). The theranostic features of NCssG NPs were fully utilized to evaluate the redox-triggered drug release process, in vivo biodistribution and tumor targeted accumulation of NCssG NPs. This work provides a novel strategy and some useful information for the optimization of the design of theranostic nDDS to benefit for the clinic application of nanodrugs in the future.
Collapse
|
17
|
Xiao H, Yan L, Dempsey EM, Song W, Qi R, Li W, Huang Y, Jing X, Zhou D, Ding J, Chen X. Recent progress in polymer-based platinum drug delivery systems. Prog Polym Sci 2018. [DOI: 10.1016/j.progpolymsci.2018.07.004] [Citation(s) in RCA: 105] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
18
|
Montagner D, Tolan D, Andriollo E, Gandin V, Marzano C. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells. Int J Mol Sci 2018; 19:ijms19123775. [PMID: 30486477 PMCID: PMC6321036 DOI: 10.3390/ijms19123775] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Revised: 11/24/2018] [Accepted: 11/26/2018] [Indexed: 12/25/2022] Open
Abstract
In this study, two DNA-targeting agents, cisplatin and chlorambucil, were combined in a Pt(IV) prodrug, 1, which was thoroughly characterized by means of spectroscopic and spectrometric techniques. Tested towards a panel of various human tumor cell lines, this compound showed superior in vitro antitumor potential than the reference drug cisplatin. In addition, an antitumor potential of 1 was found, which is comparable to that of oxaliplatin in 3D spheroid models of colon cancer cells. Mechanistic studies performed in colon cancer cells confirmed that the conjugation of chlorambucil to Pt(IV) cisplatin-based scaffold tunes the lipophilicity of the prodrug, consequently improving the ability of the compound to accumulate into cancer cells and to target DNA, ultimately leading to apoptotic cancer cell death.
Collapse
Affiliation(s)
- Diego Montagner
- Department of Chemistry, Maynooth University, Maynooth zip code, Ireland.
| | - Dina Tolan
- School of Chemistry, National University of Ireland Galway, Galway zip code, Ireland.
- Department of Chemistry, Faculty of Science, El-Menoufia University, Shebin El-Kom 32511, Egypt.
| | - Emma Andriollo
- Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Padova 35131, Italy.
| | - Valentina Gandin
- Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Padova 35131, Italy.
| | - Cristina Marzano
- Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Padova 35131, Italy.
| |
Collapse
|
19
|
Loh KP, Ho D, Chiu GNC, Leong DT, Pastorin G, Chow EKH. Clinical Applications of Carbon Nanomaterials in Diagnostics and Therapy. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2018; 30:e1802368. [PMID: 30133035 DOI: 10.1002/adma.201802368] [Citation(s) in RCA: 91] [Impact Index Per Article: 15.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/13/2018] [Revised: 05/28/2018] [Indexed: 06/08/2023]
Abstract
Nanomaterials have the potential to improve how patients are clinically treated and diagnosed. While there are a number of nanomaterials that can be used toward improved drug delivery and imaging, how these nanomaterials confer an advantage over other nanomaterials, as well as current clinical approaches is often application or disease specific. How the unique properties of carbon nanomaterials, such as nanodiamonds, carbon nanotubes, carbon nanofibers, graphene, and graphene oxides, make them promising nanomaterials for a wide range of clinical applications are discussed herein, including treating chemoresistant cancer, enhancing magnetic resonance imaging, and improving tissue regeneration and stem cell banking, among others. Additionally, the strategies for further improving drug delivery and imaging by carbon nanomaterials are reviewed, such as inducing endothelial leakiness as well as applying artificial intelligence toward designing optimal nanoparticle-based drug combination delivery. While the clinical application of carbon nanomaterials is still an emerging field of research, there is substantial preclinical evidence of the translational potential of carbon nanomaterials. Early clinically trial studies are highlighted, further supporting the use of carbon nanomaterials in clinical applications for both drug delivery and imaging.
Collapse
Affiliation(s)
- Kian Ping Loh
- Department of Chemistry and Centre for Advanced 2D Materials (CA2DM), National University of Singapore, Singapore, 117543, Singapore
| | - Dean Ho
- Department of Biomedical Engineering, National University of Singapore, Singapore, 117583, Singapore
- Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117599, Singapore
- Singapore Institute for Neurotechnology (SINAPSE), Singapore, 117456, Singapore
- Biomedical Institute for Global Health Research and Technology (BIGHEART), Singapore, 117599, Singapore
| | - Gigi Ngar Chee Chiu
- Department of Pharmacy, National University of Singapore, Singapore, 117543, Singapore
| | - David Tai Leong
- Department of Chemical and Biomolecular Engineering, National University of Singapore, Singapore, 117585, Singapore
| | - Giorgia Pastorin
- Department of Pharmacy, National University of Singapore, Singapore, 117543, Singapore
| | - Edward Kai-Hua Chow
- Cancer Science Institute of Singapore, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117599, Singapore
| |
Collapse
|
20
|
Abstract
The success of platinum-based anticancer agents has motivated the exploration of novel metal-based drugs for several decades, whereas problems such as drug-resistance and systemic toxicity hampered their clinical applications and efficacy. Stimuli-responsiveness of some metal complexes offers a good opportunity for designing site-specific prodrugs to maximize the therapeutic efficacy and minimize the side effect of metallodrugs. This review presents a comprehensive and up-to-date overview on the therapeutic stimuli-responsive metallodrugs that have appeared in the past two decades, where stimuli such as redox, pH, enzyme, light, temperature, and so forth were involved. The compounds are classified into three major categories based on the nature of stimuli, that is, endo-stimuli-responsive metallodrugs, exo-stimuli-responsive metallodrugs, and dual-stimuli-responsive metallodrugs. Representative examples of each type are discussed in terms of structure, response mechanism, and potential medical applications. In the end, future opportunities and challenges in this field are tentatively proposed. With diverse metal complexes being introduced, the foci of this review are pointed to platinum and ruthenium complexes.
Collapse
Affiliation(s)
- Xiaohui Wang
- College of Chemistry and Molecular Engineering , Nanjing Tech University , Nanjing 211816 , P. R. China
| | - Xiaoyong Wang
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences , Nanjing University , Nanjing 210023 , P. R. China
| | - Suxing Jin
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences , Nanjing University , Nanjing 210023 , P. R. China
| | - Nafees Muhammad
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry , Sun Yat-Sen University , Guangzhou 510275 , P. R. China
| | - Zijian Guo
- State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering , Nanjing University , Nanjing 210093 , P. R. China
| |
Collapse
|
21
|
Lee KGZ, Babak MV, Weiss A, Dyson PJ, Nowak-Sliwinska P, Montagner D, Ang WH. Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug. ChemMedChem 2018; 13:1210-1217. [PMID: 29637702 DOI: 10.1002/cmdc.201800105] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2018] [Revised: 03/27/2018] [Indexed: 01/19/2023]
Abstract
The cytotoxicity of cisplatin (cDDP) is enhanced when co-administered with ethacrynic acid (EA), a glutathione S-transferase (GST) inhibitor. A PtIV -EA conjugate containing a cDDP core and two axial ethacrynate ligands (compound 1) was shown to be an excellent inhibitor of GST, but did not readily release a PtII species to exert a synergistic cytotoxic effect. In this study, a redesigned PtIV construct composed of a cDDP core with one axial ethacrynate ligand and one axial hydroxido ligand (compound 2) was prepared and shown to overcome the limitations of compound 1. The EA ligand in 2 is readily released in vitro together with a cytotoxic PtII species derived from cisplatin, working together to inhibit cell proliferation in cDDP-resistant human ovarian cancer cells. The in vitro activity translates well in vivo with 2, showing effective (∼80 %) inhibition of tumor growth in a human ovarian carcinoma A2780 tumor model, while showing considerably lower toxicity than cisplatin, thus validating the new design strategy.
Collapse
Affiliation(s)
- Keefe Guang Zhi Lee
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore, 117543, Singapore
| | - Maria V Babak
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore, 117543, Singapore
| | - Andrea Weiss
- School of Pharmaceutical Science, University of Geneva (UNIGE), 1211, Geneva, Switzerland
| | - Paul J Dyson
- Institut des Sciences et Ingénierie Chimiques, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | | | - Diego Montagner
- Department of Chemistry, Maynooth University, Maynooth, Ireland
| | - Wee Han Ang
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore, 117543, Singapore
| |
Collapse
|
22
|
Shen J, Zhang W, Qi R, Mao ZW, Shen H. Engineering functional inorganic-organic hybrid systems: advances in siRNA therapeutics. Chem Soc Rev 2018; 47:1969-1995. [PMID: 29417968 PMCID: PMC5861001 DOI: 10.1039/c7cs00479f] [Citation(s) in RCA: 84] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Cancer treatment still faces a lot of obstacles such as tumor heterogeneity, drug resistance and systemic toxicities. Beyond the traditional treatment modalities, exploitation of RNA interference (RNAi) as an emerging approach has immense potential for the treatment of various gene-caused diseases including cancer. The last decade has witnessed enormous research and achievements focused on RNAi biotechnology. However, delivery of small interference RNA (siRNA) remains a key challenge in the development of clinical RNAi therapeutics. Indeed, functional nanomaterials play an important role in siRNA delivery, which could overcome a wide range of sequential physiological and biological obstacles. Nanomaterial-formulated siRNA systems have potential applications in protection of siRNA from degradation, improving the accumulation in the target tissues, enhancing the siRNA therapy and reducing the side effects. In this review, we explore and summarize the role of functional inorganic-organic hybrid systems involved in the siRNA therapeutic advancements. Additionally, we gather the surface engineering strategies of hybrid systems to optimize for siRNA delivery. Major progress in the field of inorganic-organic hybrid platforms including metallic/non-metallic cores modified with organic shells or further fabrication as the vectors for siRNA delivery is discussed to give credit to the interdisciplinary cooperation between chemistry, pharmacy, biology and medicine.
Collapse
Affiliation(s)
- Jianliang Shen
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-Sen University, Guangzhou 510275, China. and School of Ophthalmology & Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, 325035, China and Wenzhou Institute of Biomaterials and Engineering, Chinese Academy of Science, Wenzhou, 325001, China and Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, USA.
| | - Wei Zhang
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-Sen University, Guangzhou 510275, China.
| | - Ruogu Qi
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, USA.
| | - Zong-Wan Mao
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry, Sun Yat-Sen University, Guangzhou 510275, China. and Department of Applied Chemistry, South China Agricultural University, Guangzhou 510642, China
| | - Haifa Shen
- Department of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, USA. and Department of Cell and Developmental Biology, Weill Cornell Medicine, New York, NY10065, USA
| |
Collapse
|
23
|
Biagiotti G, Fedeli S, Tuci G, Luconi L, Giambastiani G, Brandi A, Pisaneschi F, Cicchi S, Paoli P. Combined therapies with nanostructured carbon materials: there is room still available at the bottom. J Mater Chem B 2018; 6:2022-2035. [PMID: 32254426 DOI: 10.1039/c8tb00121a] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The progress of the chemistry of carbon nanotubes (CNT) and graphene derivatives [mainly graphene oxide (GO)] has produced a number of technologically advanced drug delivery systems (DDS) that have been used in the field of nanomedicine, mostly in studies related to oncology. However, such a demanding field of research requires continuous improvements in terms of efficiency, selectivity and versatility. The loading of two, or more, bioactive components on the same nanoparticle offers new possibilities for treating cancer, efficiently addressing issues related both to biodistribution and pharmacokinetics. Nanostructured carbon materials (NCM), with their high surface area, their efficient cellular membrane crossing and their chemical versatility are ideal candidates for easy hetero-decoration and exploitation as advanced DDS. This review describes the achievements obtained in this area focusing on those studies in which two or more active components were loaded onto the DDS.
Collapse
Affiliation(s)
- Giacomo Biagiotti
- Department of Chemistry "Ugo Schiff", Università di Firenze, via della Lastruccia 3-13, 50019, Sesto Fiorentino, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Dai Y, Yang Z, Cheng S, Wang Z, Zhang R, Zhu G, Wang Z, Yung BC, Tian R, Jacobson O, Xu C, Ni Q, Song J, Sun X, Niu G, Chen X. Toxic Reactive Oxygen Species Enhanced Synergistic Combination Therapy by Self-Assembled Metal-Phenolic Network Nanoparticles. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2018; 30. [PMID: 29315862 DOI: 10.1002/adma.201704877] [Citation(s) in RCA: 272] [Impact Index Per Article: 45.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/25/2017] [Revised: 10/13/2017] [Indexed: 05/11/2023]
Abstract
Engineering functional nanomaterials with high therapeutic efficacy and minimum side effects has increasingly become a promising strategy for cancer treatment. Herein, a reactive oxygen species (ROS) enhanced combination chemotherapy platform is designed via a biocompatible metal-polyphenol networks self-assembly process by encapsulating doxorubicin (DOX) and platinum prodrugs in nanoparticles. Both DOX and platinum drugs can activate nicotinamide adenine dinucleotide phosphate oxidases, generating superoxide radicals (O2•- ). The superoxide dismutase-like activity of polyphenols can catalyze H2 O2 generation from O2•- . Finally, the highly toxic HO• free radicals are generated by a Fenton reaction. The ROS HO• can synergize the chemotherapy by a cascade of bioreactions. Positron emission tomography imaging of 89 Zr-labeled as-prepared DOX@Pt prodrug Fe3+ nanoparticles (DPPF NPs) shows prolonged blood circulation and high tumor accumulation. Furthermore, the DPPF NPs can effectively inhibit tumor growth and reduce the side effects of anticancer drugs. This study establishes a novel ROS promoted synergistic nanomedicine platform for cancer therapy.
Collapse
Affiliation(s)
- Yunlu Dai
- Engineering Research Center of Molecular-imaging and Neuro-imaging of Ministry of Education, School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, 710126, China
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
| | - Zhen Yang
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
| | - Siyuan Cheng
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
| | - Zhongliang Wang
- Engineering Research Center of Molecular-imaging and Neuro-imaging of Ministry of Education, School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, 710126, China
| | - Ruili Zhang
- Engineering Research Center of Molecular-imaging and Neuro-imaging of Ministry of Education, School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, 710126, China
| | - Guizhi Zhu
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
| | - Zhantong Wang
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
| | - Bryant C Yung
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
| | - Rui Tian
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
| | - Orit Jacobson
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
| | - Can Xu
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
| | - Qianqian Ni
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
| | - Jibin Song
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
| | - Xiaolian Sun
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, 361005, China
| | - Gang Niu
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
| | - Xiaoyuan Chen
- Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD, 20892, USA
| |
Collapse
|
25
|
Mitra K. Platinum complexes as light promoted anticancer agents: a redefined strategy for controlled activation. Dalton Trans 2018; 45:19157-19171. [PMID: 27883129 DOI: 10.1039/c6dt03665a] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Site-specific delivery and amenable activation of prodrugs are indispensible criteria for designing novel anticancer agents. Platinum based drugs vanguard the chemotherapeutic regimes and over the years significant attention has been paid to achieve more efficacious drugs with fewer adverse effects. The switch from platinum(ii) drugs to the inert platinum(iv) analogues proved advantageous but the new prodrugs still suffered from unspecific cytotoxic actions. Thus the photoactivation of an inert platinum prodrug specifically within neoplastic cells provided the desired spatio-temporal control over drug activation by means of illumination, thereby limiting the cytotoxic events to only at the targeted tumors. This article collates research on platinum complexes which exhibit potential light mediated anticancer effects and provides insights into the underlying mechanisms of activation. Fine tuning of the coordination sphere results in dramatic alteration of the redox and spectral properties of both ground and excited states and the cellular properties of the molecules. This concise article highlights the various light promoted strategies employed to attain a controlled release of active platinum(ii) and/or reactive oxygen species such as photoreduction, photocaging, photodissociation and photosensitization. Such dual action photoactive metal complexes with improved aqueous solubility and versatility are promising candidates for combination therapy which is likely to be the future of anticancer research.
Collapse
Affiliation(s)
- Koushambi Mitra
- Department of Inorganic and Physical Chemistry, Indian Institute of Science, Bangalore 560-012, India.
| |
Collapse
|
26
|
Basu U, Banik B, Wen R, Pathak RK, Dhar S. The Platin-X series: activation, targeting, and delivery. Dalton Trans 2018; 45:12992-3004. [PMID: 27493131 DOI: 10.1039/c6dt01738j] [Citation(s) in RCA: 76] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Anticancer platinum (Pt) complexes have long been considered to be one of the biggest success stories in the history of medicinal inorganic chemistry. Yet there remains the hunt for the "magic bullet" which can satisfy the requirements of an effective chemotherapeutic drug formulation. Pt(iv) complexes are kinetically more inert than the Pt(ii) congeners and offer the opportunity to append additional functional groups/ligands for prodrug activation, tumor targeting, or drug delivery. The ultimate aim of functionalization is to enhance the tumor selective action and attenuate systemic toxicity of the drugs. Moreover, an increase in cellular accumulation to surmount the resistance of the tumor against the drugs is also of paramount importance in drug development and discovery. In this review, we will address the attempts made in our lab to develop Pt(iv) prodrugs that can be activated and delivered using targeted nanotechnology-based delivery platforms.
Collapse
Affiliation(s)
- Uttara Basu
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA
| | - Bhabatosh Banik
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA
| | - Ru Wen
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA
| | - Rakesh K Pathak
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA
| | - Shanta Dhar
- NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA
| |
Collapse
|
27
|
Conibear AC, Hager S, Mayr J, Klose MHM, Keppler BK, Kowol CR, Heffeter P, Becker CFW. Multifunctional α vβ 6 Integrin-Specific Peptide-Pt(IV) Conjugates for Cancer Cell Targeting. Bioconjug Chem 2017; 28:2429-2439. [PMID: 28796473 DOI: 10.1021/acs.bioconjchem.7b00421] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Increasing the specificity of cancer therapy, and thereby decreasing damage to normal cells, requires targeting to cancer-cell specific features. The αvβ6 integrin is a receptor involved in cell adhesion and is frequently up-regulated in cancer cells compared to normal cells. We have selected a peptide ligand reported to bind specifically to the β6 integrin and have synthesized a suite of multispecific molecules to explore the potential for targeting of cancer cells. A combination of solid-phase peptide synthesis and chemoselective ligations was used to synthesize multifunctional molecules composed of integrin-targeting peptides, cytotoxic platinum(IV) prodrugs, and fluorescent or affinity probes joined with flexible linkers. The modular synthesis approach facilitates the construction of peptide-drug conjugates with various valencies and properties in a convergent manner. The binding and specificity of the multifunctional peptide conjugates were investigated using a cell line transfected with the β6 integrin and fluorescence microscopy. This versatile and highly controlled approach to synthesizing labeled peptide-drug conjugates has the potential to target potent cytotoxic drugs specifically to cancer cells, reducing the doses required for effective treatment.
Collapse
Affiliation(s)
- Anne C Conibear
- Faculty of Chemistry, Institute of Biological Chemistry, University of Vienna , Währinger Straße 38, 1090 Vienna, Austria
| | - Sonja Hager
- Institute of Cancer Research and Comprehensive Cancer Centre, Medical University of Vienna , Borschkegasse 8a, 1090 Vienna, Austria
| | - Josef Mayr
- Institute of Inorganic Chemistry, University of Vienna, Faculty of Chemistry , Währinger Straße 42, 1090 Vienna, Austria
| | - Matthias H M Klose
- Institute of Inorganic Chemistry, University of Vienna, Faculty of Chemistry , Währinger Straße 42, 1090 Vienna, Austria
| | - Bernhard K Keppler
- Institute of Inorganic Chemistry, University of Vienna, Faculty of Chemistry , Währinger Straße 42, 1090 Vienna, Austria
| | - Christian R Kowol
- Institute of Inorganic Chemistry, University of Vienna, Faculty of Chemistry , Währinger Straße 42, 1090 Vienna, Austria
| | - Petra Heffeter
- Institute of Cancer Research and Comprehensive Cancer Centre, Medical University of Vienna , Borschkegasse 8a, 1090 Vienna, Austria
| | - Christian F W Becker
- Faculty of Chemistry, Institute of Biological Chemistry, University of Vienna , Währinger Straße 38, 1090 Vienna, Austria
| |
Collapse
|
28
|
Zhong P, Qiu M, Zhang J, Sun H, Cheng R, Deng C, Meng F, Zhong Z. cRGD-installed docetaxel-loaded mertansine prodrug micelles: redox-triggered ratiometric dual drug release and targeted synergistic treatment of B16F10 melanoma. NANOTECHNOLOGY 2017; 28:295103. [PMID: 28574851 DOI: 10.1088/1361-6528/aa76cc] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Combinatorial chemotherapy, which has emerged as a promising treatment modality for intractable cancers, is challenged by a lack of tumor-targeting, robust and ratiometric dual drug release systems. Here, docetaxel-loaded cRGD peptide-decorated redox-activable micellar mertansine prodrug (DTX-cRGD-MMP) was developed for targeted and synergistic treatment of B16F10 melanoma-bearing C57BL/6 mice. DTX-cRGD-MMP exhibited a small size of ca. 49 nm, high DTX and DM1 loading, low drug leakage under physiological conditions, with rapid release of both DTX and DM1 under a cytoplasmic reductive environment. Notably, MTT and flow cytometry assays showed that DTX-cRGD-MMP brought about a synergistic antitumor effect to B16F10 cancer cells, with a combination index of 0.37 and an IC50 over 3- and 13-fold lower than cRGD-MMP (w/o DTX) and DTX-cRGD-Ms (w/o DM1) controls, respectively. In vivo studies revealed that DTX-cRGD-MMP had a long circulation time and a markedly improved accumulation in the B16F10 tumor compared with the non-targeting DTX-MMP control (9.15 versus 3.13% ID/g at 12 h post-injection). Interestingly, mice treated with DTX-cRGD-MMP showed almost complete growth inhibition of B16F10 melanoma, with tumor inhibition efficacy following an order of DTX-cRGD-MMP > DTX-MMP (w/o cRGD) > cRGD-MMP (w/o DTX) > DTX-cRGD-Ms (w/o DM1) > free DTX. Consequently, DTX-cRGD-MMP significantly improved the survival rates of B16F10 melanoma-bearing mice. Importantly, DTX-cRGD-MMP caused little adverse effects as revealed by mice body weights and histological analyses. The combination of two mitotic inhibitors, DTX and DM1, appears to be an interesting approach for effective cancer therapy.
Collapse
Affiliation(s)
- Ping Zhong
- Biomedical Polymers Laboratory, and Jiangsu Key Laboratory of Advanced Functional Polymer Design and Application, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou, 215123, People's Republic of China
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Feng T, Chua HJ, Zhao Y. Reduction-Responsive Carbon Dots for Real-Time Ratiometric Monitoring of Anticancer Prodrug Activation in Living Cells. ACS Biomater Sci Eng 2017; 3:1535-1541. [PMID: 33429640 DOI: 10.1021/acsbiomaterials.7b00264] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Anticancer prodrugs have been extensively investigated to lower toxic side effects of common chemotherapeutic agents in biomedical fields. To illustrate the activation mechanism of anticancer prodrugs, fluorescent dyes or single-emission intensity alteration-based approaches have been widely used. However, fluorescent dyes often suffer from poor photostability and chemical stability, and single-emission intensity alteration-based methods cannot avoid the influence from uncontrolled microenvironment changes in living samples. To overcome these obstacles, herein, a fluorescence resonance energy transfer (FRET)-based ratiometric approach was successfully developed for real-time monitoring of anticancer prodrug activation. Excitation-wavelength-dependent and full-color-emissive carbon dots (CDs) were used as drug nanocarriers and FRET donor, and a cisplatin(IV) prodrug was selected as the model drug and the linker to load the Dabsyl quencher on the surface of CDs. Owing to the FRET effect, the blue fluorescence of CDs was effectively quenched by the Dabsyl unit. Under reductive conditions in solution or in living cells for the reduction of cisplatin(IV) prodrug to Pt(II) species, the blue fluorescence of CDs increased over time, without apparent intensity change for green or red fluorescence. Thus, the gradually enhanced intensity ratio of blue-to-green or blue-to-red fluorescence could be indicative of the real-time reduction of the cisplatin(IV) prodrug to cytotoxic Pt(II) species. This ratiometric method could exclude the influence from complex biological microenvironments by using green or red fluorescence of CDs as an internal reference, which provides new insights into the activation of the cisplatin(IV) prodrug and offers a great opportunity to design safe and effective anticancer therapeutics.
Collapse
Affiliation(s)
- Tao Feng
- Division of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, 637371 Singapore
| | - Huoy Jing Chua
- Division of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, 637371 Singapore
| | - Yanli Zhao
- Division of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, Nanyang Technological University, 21 Nanyang Link, 637371 Singapore.,School of Materials Science and Engineering, Nanyang Technological University, 50 Nanyang Avenue, 639798 Singapore
| |
Collapse
|
30
|
Misra C, Kumar M, Sharma G, Kumar R, Singh B, Katare OP, Raza K. Glycinated fullerenes for tamoxifen intracellular delivery with improved anticancer activity and pharmacokinetics. Nanomedicine (Lond) 2017; 12:1011-1023. [DOI: 10.2217/nnm-2016-0432] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Aim: Glycine-tethered C60-fullerenes were conjugated with N-desmethyl tamoxifen and evaluated for drug delivery benefits. Materials & methods: C60-fullerenes were functionalized with glycine, and N-desmethyl tamoxifen was conjugated, employing a linker and characterized for micromeritics, drug loading, drug release and evaluated for cancer cell toxicity, cellular uptake and pharmacokinetics. Results: The nanoconjugate with a drug entrapment efficiency of 82.71 ± 6.23% and a drug loading of 66.01 ± 4.98% was hemocompatibile with appreciable MCF-7 cytotoxicity. The confocal results confirmed enhanced uptake of conjugate. Interestingly, pharmacokinetic outcomes of the conjugate were superior and the area under the curve was enhanced by approximately three-times, whereas the drug clearance was reduced by around five-times, after single intravenous injection. Conclusion: The conjugation assured improved availability of drug in a biological system for prolonged duration as well as in the interiors of target cells with a promise of enhanced efficacy and compatibility.
Collapse
Affiliation(s)
- Charu Misra
- Department of Pharmacy, School of Chemical Sciences & Pharmacy, Central University of Rajasthan, Bandar Sindri, Ajmer, Rajasthan 305817, India
| | - Manish Kumar
- Department of Pharmacy, School of Chemical Sciences & Pharmacy, Central University of Rajasthan, Bandar Sindri, Ajmer, Rajasthan 305817, India
| | - Gajanand Sharma
- University Institute of Pharmaceutical Sciences, UGC-Centre of Advanced Studies, Panjab University, Chandigarh 160014, India
| | - Rajendra Kumar
- UGC-Centre of Excellence in Applications of Nanomaterials, Nanoparticles & Nanocomposites, Panjab University, Chandigarh 160014, India
| | - Bhupinder Singh
- University Institute of Pharmaceutical Sciences, UGC-Centre of Advanced Studies, Panjab University, Chandigarh 160014, India
- UGC-Centre of Excellence in Applications of Nanomaterials, Nanoparticles & Nanocomposites, Panjab University, Chandigarh 160014, India
| | - Om Prakash Katare
- UGC-Centre of Excellence in Applications of Nanomaterials, Nanoparticles & Nanocomposites, Panjab University, Chandigarh 160014, India
| | - Kaisar Raza
- Department of Pharmacy, School of Chemical Sciences & Pharmacy, Central University of Rajasthan, Bandar Sindri, Ajmer, Rajasthan 305817, India
| |
Collapse
|
31
|
Skoczynska A, Małecka M, Cieslak M, Kazmierczak-Baranska J, Krolewska-Golinska K, Leniart A, Budzisz E. Synthesis, structural analysis, redox properties and in vitro antitumor evaluation of half-sandwich complexes of Ru(II) with aminocoumarins. Polyhedron 2017. [DOI: 10.1016/j.poly.2017.02.011] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
32
|
Wu H, Jin H, Wang C, Zhang Z, Ruan H, Sun L, Yang C, Li Y, Qin W, Wang C. Synergistic Cisplatin/Doxorubicin Combination Chemotherapy for Multidrug-Resistant Cancer via Polymeric Nanogels Targeting Delivery. ACS APPLIED MATERIALS & INTERFACES 2017; 9:9426-9436. [PMID: 28247750 DOI: 10.1021/acsami.6b16844] [Citation(s) in RCA: 111] [Impact Index Per Article: 15.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Combination chemotherapy has been proposed to achieve synergistic effect and minimize drug dose for cancer treatment in clinic application. In this article, the stimuli-responsive polymeric nanogels (<100 nm in size) based on poly(acrylic acid) were designed as codelivery system for doxorubicin and cisplatin to overcome drug resistance. By chelation, electrostatic interaction, and π-π stacking interactions, the nanogels could encapsulate doxorubicin and cisplatin with designed ratio and high capacity. Compared with free drugs, the nanogels could deliver more drugs into MCF-7/ADR cells. Significant accumulation in tumor tissues was observed in the biodistribution experiments. The in vitro antitumor studies demonstrated the superior cell-killing activity of the nanogel drug delivery system with a combination index of 0.84, which indicated the great synergistic effect. All the antitumor experimental data revealed that the combination therapy was effective for the multidrug-resistant MCF-7/ADR tumor with reduced side effects.
Collapse
Affiliation(s)
- Haiqiu Wu
- State Key Laboratory of Molecular Engineering of Polymers, and Department of Macromolecular Science, Laboratory of Advanced Materials, Fudan University , Shanghai 200433, China
| | - Haojie Jin
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200030, China
| | - Cun Wang
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200030, China
| | - Zihao Zhang
- State Key Laboratory of Molecular Engineering of Polymers, and Department of Macromolecular Science, Laboratory of Advanced Materials, Fudan University , Shanghai 200433, China
| | - Haoyu Ruan
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200030, China
| | - Luyan Sun
- State Key Laboratory of Molecular Engineering of Polymers, and Department of Macromolecular Science, Laboratory of Advanced Materials, Fudan University , Shanghai 200433, China
| | - Chen Yang
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200030, China
| | - Yongjing Li
- State Key Laboratory of Molecular Engineering of Polymers, and Department of Macromolecular Science, Laboratory of Advanced Materials, Fudan University , Shanghai 200433, China
| | - Wenxin Qin
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200030, China
| | - Changchun Wang
- State Key Laboratory of Molecular Engineering of Polymers, and Department of Macromolecular Science, Laboratory of Advanced Materials, Fudan University , Shanghai 200433, China
| |
Collapse
|
33
|
Yap SQ, Chin CF, Hong Thng AH, Pang YY, Ho HK, Ang WH. Finely Tuned Asymmetric Platinum(IV) Anticancer Complexes: Structure-Activity Relationship and Application as Orally Available Prodrugs. ChemMedChem 2017; 12:300-311. [PMID: 28028938 DOI: 10.1002/cmdc.201600577] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2016] [Revised: 12/22/2016] [Indexed: 01/12/2023]
Abstract
Platinum(IV) bis-carboxylates are highly versatile prodrug scaffolds with different axial ligands that can be functionalized while keeping the platinum(II) pharmacophore intact. Using a sequential acylation strategy, we developed a class of PtIV prodrugs of cisplatin with contrasting lipophilic and hydrophilic ligands. We investigated their stability, reduction rates, lipophilicity, aqueous solubility, and antiproliferative efficacies, and assessed for correlations among the parameters that could be useful in drug design. We showed that compounds with high lipophilicity result in better antiproliferative effects in vitro and in vivo, with one of the three compounds tested showing better efficacy than satraplatin against an animal model of colorectal cancer, owing to its higher solubility and lower reduction rates. Our asymmetric PtIV prodrugs may pave the way for a highly predictable, fine-tuned class of orally available PtIV prodrugs for the treatment of colorectal cancer.
Collapse
Affiliation(s)
- Siew Qi Yap
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore, 117543, Singapore
| | - Chee Fei Chin
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore, 117543, Singapore
| | - Agnes Hwee Hong Thng
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore, 117543, Singapore
| | - Yi Yun Pang
- Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore, 117543, Singapore
| | - Han Kiat Ho
- Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore, 117543, Singapore.,NUS Graduate School of Integrative Sciences and Engineering, National University of Singapore, 28 Medical Drive, Singapore, 117456, Singapore
| | - Wee Han Ang
- Department of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore, 117543, Singapore.,NUS Graduate School of Integrative Sciences and Engineering, National University of Singapore, 28 Medical Drive, Singapore, 117456, Singapore
| |
Collapse
|
34
|
Yan QQ, Yuan Z, Liu GJ, Lv ZH, Fu B, Du JL, Li LJ. Synthesis, characterization and cytotoxicity of platinum(II) complexes containing reduced amino acid ester Schiff bases. Appl Organomet Chem 2016. [DOI: 10.1002/aoc.3689] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Qin-Qin Yan
- College of Chemistry and Environmental Science; Chemical Biology Key Laboratory of Hebei Province; Hebei University; Baoding 071002 China
| | - Zhen Yuan
- College of Chemistry and Environmental Science; Chemical Biology Key Laboratory of Hebei Province; Hebei University; Baoding 071002 China
| | - Guo-Jun Liu
- College of Chemistry and Environmental Science; Chemical Biology Key Laboratory of Hebei Province; Hebei University; Baoding 071002 China
| | - Zheng-Hua Lv
- College of Chemistry and Environmental Science; Chemical Biology Key Laboratory of Hebei Province; Hebei University; Baoding 071002 China
| | - Bin Fu
- College of Chemistry and Environmental Science; Chemical Biology Key Laboratory of Hebei Province; Hebei University; Baoding 071002 China
| | - Jian-Long Du
- College of Chemistry and Environmental Science; Chemical Biology Key Laboratory of Hebei Province; Hebei University; Baoding 071002 China
| | - Li-Jun Li
- College of Chemistry and Environmental Science; Chemical Biology Key Laboratory of Hebei Province; Hebei University; Baoding 071002 China
| |
Collapse
|
35
|
Cao Z, Zhou X, Wang G. Selective Release of Hydrophobic and Hydrophilic Cargos from Multi-Stimuli-Responsive Nanogels. ACS APPLIED MATERIALS & INTERFACES 2016; 8:28888-28896. [PMID: 27700021 DOI: 10.1021/acsami.6b10360] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Highly stable multi-stimuli-responsive nanogels for selective release of simultaneously encapsulated hydrophobic and hydrophilic cargos in a spatiotemporally controlled manner are demonstrated here. The nanogel is composed of hydrophilic pH- and thermoresponsive poly(2-(dimethylamino)ethyl methacrylate) (PDMAEMA) and hydrophobic photocleavable o-nitrobenzyl (ONB) linkage. The hydrophobic cargos were noncovalently encapsulated into lipophilic interiors of the nanogels, while the hydrophilic cargos were chemically linked to the nanogel precursor polymer PDMAEMA through a redox-cleavable disulfide junction. For these dual-loaded nanogels, hydrophobic cargos can be released in response to temperature, pH, and UV light, while the hydrophilic cargos can be released in response to redox reagent. The stimuli-selective release of hydrophobic and hydrophilic cargos affords the system with great potential applications in combination chemotherapy, tissue engineering, anticorrosion, and smart nanoreactors.
Collapse
Affiliation(s)
- Ziquan Cao
- School of Materials Science and Engineering, University of Science and Technology Beijing , Beijing 100083, China
| | - Xiaoteng Zhou
- School of Materials Science and Engineering, University of Science and Technology Beijing , Beijing 100083, China
| | - Guojie Wang
- School of Materials Science and Engineering, University of Science and Technology Beijing , Beijing 100083, China
| |
Collapse
|
36
|
Huang X, Huang R, Gou S, Wang Z, Liao Z, Wang H. Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt(IV) Moiety with a Unique Mode of Action. Bioconjug Chem 2016; 27:2132-48. [PMID: 27494235 DOI: 10.1021/acs.bioconjchem.6b00353] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Three new Pt(IV) complexes comprising a combretastatin A-4 analogue were designed and synthesized. The resulting antitumor Pt(IV) complexes could significantly improve the antiproliferative activity and overcome the drug resistance of cisplatin in vitro. Interestingly, these novel compounds not only can carry the DNA binding Pt(II) warhead into the cancer cells but also have a small molecule fragment that can inhibit tubulin polymerization. Among them, complex 13, which was attached to an inhibitor of tubulin at one axial position of Pt(IV) octahedral coordination sphere, could effectively enter cancer cells, arrest the cell cycle in HepG-2 cancer cells at G2/M phases, and induce activation of caspases triggering apoptotic signaling via the mitochondrial-dependent apoptosis pathways. Moreover, complex 13 has the ability to effectively inhibit the tumor growth in the HepG-2 xenograft model without causing significant loss of animal body weight in comparison with cisplatin.
Collapse
Affiliation(s)
| | | | | | | | | | - Hengshan Wang
- State Key Laboratory for the Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), School of Chemistry and Pharmaceutical Sciences of Guangxi Normal University , Guilin 541004, China
| |
Collapse
|
37
|
Castillo RR, Colilla M, Vallet-Regí M. Advances in mesoporous silica-based nanocarriers for co-delivery and combination therapy against cancer. Expert Opin Drug Deliv 2016; 14:229-243. [DOI: 10.1080/17425247.2016.1211637] [Citation(s) in RCA: 116] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Rafael R. Castillo
- Departamento de Química Inorgánica y Bioinorgánica. Facultad de Farmacia, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12, Madrid, Spain
- Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| | - Montserrat Colilla
- Departamento de Química Inorgánica y Bioinorgánica. Facultad de Farmacia, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12, Madrid, Spain
- Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| | - María Vallet-Regí
- Departamento de Química Inorgánica y Bioinorgánica. Facultad de Farmacia, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12, Madrid, Spain
- Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| |
Collapse
|
38
|
Zhang W, Shen J, Su H, Mu G, Sun JH, Tan CP, Liang XJ, Ji LN, Mao ZW. Co-Delivery of Cisplatin Prodrug and Chlorin e6 by Mesoporous Silica Nanoparticles for Chemo-Photodynamic Combination Therapy to Combat Drug Resistance. ACS APPLIED MATERIALS & INTERFACES 2016; 8:13332-13340. [PMID: 27164222 DOI: 10.1021/acsami.6b03881] [Citation(s) in RCA: 142] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Combination therapy shows great promise in circumventing cisplatin resistance. We report herein the development of a novel nanoscale drug delivery system (nDDS) based nanotherapeutic that combines chemotherapy and photodynamic therapy (PDT) into one single platform to achieve synergistic anticancer capacity to conquer cisplatin resistance. Mesoporous silica nanoparticle (MSNs) was used as the drug delivery vector to conjugate cisplatin prodrug and to load photosensitizer chlorin e6 (Ce6) to afford the dual drug loaded delivery system MSNs/Ce6/Pt. The hybrid nanoparticles have an average diameter of about 100 nm and slightly positive surface charge of about 18.2 mV. The MSNs/Ce6/Pt nanoparticles can be efficiently internalized by cells through endocytosis, thereby achieving much higher cellular Pt uptake than cisplatin in cisplatin-resistant A549R lung cancer cells. After 660 nm light irradiation (10 mW/cm(2)), the cellular reactive oxygen species (ROS) level in MSNs/Ce6/Pt treated cells was elevated dramatically. As a result of these properties, MSNs/Ce6/Pt exhibited very potent anticancer activity against A549R cells, giving a half-maximal inhibitory concentration (IC50) value for the combination therapy of 0.53 μM, much lower than that of cisplatin (25.1 μM). This study suggests the great potential of nDDS-based nanotherapeutic for combined chemo-photodynamic therapy to circumvent cisplatin resistance.
Collapse
Affiliation(s)
- Wei Zhang
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry and Chemical Engineering, Sun Yat-sen University , Guangzhou 510275, P. R. China
- CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biological Effects of Nanomaterials & Nanosafety, National Center for Nanoscience and Technology , Beijing 100190, P. R. China
| | - Jianliang Shen
- Department of Nanomedicine, Houston Methodist Research Institute , Houston, Texas 77030, United States
| | - Hua Su
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry and Chemical Engineering, Sun Yat-sen University , Guangzhou 510275, P. R. China
| | - Ge Mu
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry and Chemical Engineering, Sun Yat-sen University , Guangzhou 510275, P. R. China
| | - Jing-Hua Sun
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry and Chemical Engineering, Sun Yat-sen University , Guangzhou 510275, P. R. China
| | - Cai-Ping Tan
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry and Chemical Engineering, Sun Yat-sen University , Guangzhou 510275, P. R. China
| | - Xing-Jie Liang
- CAS Center for Excellence in Nanoscience, CAS Key Laboratory for Biological Effects of Nanomaterials & Nanosafety, National Center for Nanoscience and Technology , Beijing 100190, P. R. China
| | - Liang-Nian Ji
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry and Chemical Engineering, Sun Yat-sen University , Guangzhou 510275, P. R. China
| | - Zong-Wan Mao
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry and Chemical Engineering, Sun Yat-sen University , Guangzhou 510275, P. R. China
| |
Collapse
|
39
|
Cao H, Yang Y, Chen X, Shao Z. Intelligent Janus nanoparticles for intracellular real-time monitoring of dual drug release. NANOSCALE 2016; 8:6754-6760. [PMID: 26952741 DOI: 10.1039/c6nr00987e] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Stimuli-responsive nanomaterials have been receiving much attention as drug delivery carriers, however understanding of multi-drug release from the carriers for efficient therapeutics is highly challenging. Here, we report a novel nanosystem, Janus particle Dox-CMR-MS/Au-6MP (Dox: doxorubicin, CMR: 7-hydroxycoumarin-3-carboxylate, MS: mesoporous silica, Au: gold, 6MP: 6-mercaptopurine) with opposing MS and Au faces, which can monitor intracellular dual-drug (Dox and 6MP) controlled release in real time based on fluorescence resonance energy transfer (FRET) and surface-enhanced Raman scattering (SERS). The FRET acceptor Dox is attached to CMR (as a FRET donor) conjugated MS with a pH-responsive linker hydrazone, and 6MP is conjugated to the Au surface through the gold-thiol interaction. As the Janus nanoparticle enters into tumor cells, the breakage of the hydrazone bond in an acidic environment and the substitution of glutathione (GSH) overexpressed in cancer cells give rise to the release of Dox and 6MP, respectively. Thus, the change of the CMR fluorescence signal and the SERS decrease of 6MP can be used to monitor the dual-drug release within living cells in real time. In addition, this work demonstrates the enhanced anticancer effect of the designed dual-drug loaded nanosystem. Therefore, the current study may provide new perspectives for the real-time study of intelligent multi-drug delivery and release, as well as cellular responses to drug treatment.
Collapse
Affiliation(s)
- Han Cao
- State Key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science and Laboratory of Advanced Materials, Fudan University, Shanghai, 200433, P. R. China.
| | - Yuhong Yang
- Research Center for Analysis and Measurement, Fudan University, Shanghai, 200433, P. R. China.
| | - Xin Chen
- State Key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science and Laboratory of Advanced Materials, Fudan University, Shanghai, 200433, P. R. China.
| | - Zhengzhong Shao
- State Key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science and Laboratory of Advanced Materials, Fudan University, Shanghai, 200433, P. R. China.
| |
Collapse
|
40
|
Johnstone TC, Suntharalingam K, Lippard SJ. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs. Chem Rev 2016; 116:3436-86. [PMID: 26865551 PMCID: PMC4792284 DOI: 10.1021/acs.chemrev.5b00597] [Citation(s) in RCA: 1700] [Impact Index Per Article: 212.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new platinum agents have been very slow to enter the clinic. Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs. The use of nanodelivery devices has also grown, and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs. In this Review, we discuss these efforts to create the next generation of platinum anticancer drugs. The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished. We then describe approaches that explore nonclassical platinum(II) complexes with trans geometry or with a monofunctional coordination mode, polynuclear platinum(II) compounds, platinum(IV) prodrugs, dual-threat agents, and photoactivatable platinum(IV) complexes. Nanoparticles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles. Additional nanoformulations, including supramolecular self-assembled structures, proteins, peptides, metal-organic frameworks, and coordination polymers, will then be described. Finally, the significant clinical progress made by nanoparticle formulations of platinum(II) agents will be reviewed. We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also will reflect our optimism that the next generation of approved platinum cancer drugs is about to arrive.
Collapse
Affiliation(s)
- Timothy C Johnstone
- Department of Chemistry, Massachusetts Institute of Technology , Cambridge, Massachusetts 02139, United States
| | | | - Stephen J Lippard
- Department of Chemistry, Massachusetts Institute of Technology , Cambridge, Massachusetts 02139, United States
| |
Collapse
|
41
|
Gong Q, Shi W, Li L, Ma H. Leucine aminopeptidase may contribute to the intrinsic resistance of cancer cells toward cisplatin as revealed by an ultrasensitive fluorescent probe. Chem Sci 2016; 7:788-792. [PMID: 28966770 PMCID: PMC5580032 DOI: 10.1039/c5sc03600c] [Citation(s) in RCA: 75] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2015] [Accepted: 10/22/2015] [Indexed: 01/18/2023] Open
Abstract
Cisplatin, a typical anticancer drug, is often used to treat different cancers, and leucine aminopeptidase (LAP) is known to be widely distributed in organisms from bacteria to humans, including various cancer cells. However, cancer cells display different intrinsic or acquired resistance toward cisplatin, and it is unclear whether intracellular LAP plays a role in the intrinsic drug resistance, mainly due to the lack of a sensitive detection approach for LAP because this enzyme usually exists at trace levels in cancer cells. Herein, by developing an ultrasensitive LAP fluorescent probe (detection limit 0.42 ng mL-1) and combining it with confocal fluorescence imaging, we analyze the concentration change of LAP in cancer cells such as HepG2 and A549 cells under cisplatin treatment. We find that a large increase in the LAP concentration occurs in HepG2 rather than in A549 cells. These different changes are further confirmed by an ELISA kit. A cell viability assay reveals that HepG2 cells with a higher level of LAP have much stronger resistance toward cisplatin than A549 cells, suggesting that LAP may serve as a simple indicator to reflect the relative resistance of different cancer cells. Importantly, inhibiting the expression of LAP with siRNA further decreases cell viability. These findings support that LAP may contribute to the intrinsic resistance of cancer cells toward cisplatin. In addition, the proposed probe may find more uses in studying the cellular LAP function, and improving chemotherapeutic cancer treatment.
Collapse
Affiliation(s)
- Qiuyu Gong
- Beijing National Laboratory for Molecular Sciences , Key Laboratory of Analytical Chemistry for Living Biosystems , Institute of Chemistry , Chinese Academy of Sciences , Beijing 100190 , China .
| | - Wen Shi
- Beijing National Laboratory for Molecular Sciences , Key Laboratory of Analytical Chemistry for Living Biosystems , Institute of Chemistry , Chinese Academy of Sciences , Beijing 100190 , China .
| | - Lihong Li
- Beijing National Laboratory for Molecular Sciences , Key Laboratory of Analytical Chemistry for Living Biosystems , Institute of Chemistry , Chinese Academy of Sciences , Beijing 100190 , China .
| | - Huimin Ma
- Beijing National Laboratory for Molecular Sciences , Key Laboratory of Analytical Chemistry for Living Biosystems , Institute of Chemistry , Chinese Academy of Sciences , Beijing 100190 , China .
| |
Collapse
|
42
|
Ruan Z, Liu L, Fu L, Xing T, Yan L. An amphiphilic block copolymer conjugated with carborane and a NIR fluorescent probe for potential imaging-guided BNCT therapy. Polym Chem 2016. [DOI: 10.1039/c6py00799f] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A carborane-containing triblock copolymer conjugated with a near infrared (NIR) fluorescence probe has been synthesized via reversible addition fragmentation chain transfer (RAFT), ring open polymerization (ROP), and conjugations of a cyanine NIR dye.
Collapse
Affiliation(s)
- Zheng Ruan
- CAS Key Laboratory of Soft Matter Chemistry
- Hefei National Laboratory for Physical Sciences at the Microscale
- and National Synchrotron Radiation Laboratory
- iChEM
- University of Science and Technology of China
| | - Le Liu
- CAS Key Laboratory of Soft Matter Chemistry
- Hefei National Laboratory for Physical Sciences at the Microscale
- and National Synchrotron Radiation Laboratory
- iChEM
- University of Science and Technology of China
| | - Liyi Fu
- CAS Key Laboratory of Soft Matter Chemistry
- Hefei National Laboratory for Physical Sciences at the Microscale
- and National Synchrotron Radiation Laboratory
- iChEM
- University of Science and Technology of China
| | - Tao Xing
- Institute of System and Engineering
- Chinese Academy of Engineering Physics
- Mianyang
- China
| | - Lifeng Yan
- CAS Key Laboratory of Soft Matter Chemistry
- Hefei National Laboratory for Physical Sciences at the Microscale
- and National Synchrotron Radiation Laboratory
- iChEM
- University of Science and Technology of China
| |
Collapse
|
43
|
Dual drug delivery of tamoxifen and quercetin: Regulated metabolism for anticancer treatment with nanosponges. J Control Release 2015; 220:751-7. [DOI: 10.1016/j.jconrel.2015.08.052] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2015] [Revised: 08/21/2015] [Accepted: 08/26/2015] [Indexed: 11/23/2022]
|
44
|
Huang CC, Liu TM. Controlled Au-Polymer Nanostructures for Multiphoton Imaging, Prodrug Delivery, and Chemo-Photothermal Therapy Platforms. ACS APPLIED MATERIALS & INTERFACES 2015; 7:25259-69. [PMID: 26501876 DOI: 10.1021/acsami.5b07110] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
We have successfully introduced a proton-induced controlled reaction of HAuCl4 and poly(styrene-alt-maleic acid) (PSMA) sodium salt to prepare triangular and multicore Au@polymer nanoparticles (NPs). The interparticle interactions in the core gave rise to an absorption band at the near-infrared wavelength. The near-infrared optical properties of the resulting Au-polymer nanostructures are highly stable in a physiological environment, which offered strong photo-to-thermal conversion by a moderate continuous-wave 808 nm laser and exhibited multiphoton fluorescence for imaging using a 1230 nm light excitation (femtosecond laser). Exposure of the carboxylate groups at the polymer shell made the surface structure of the Au multicore @polymer NPs directly conjugate Pt(II)-/Pt(IV)-based drugs, which possessed the elimination of the immediate toxicity over the short time and resulted in an anticancer effect after 3 days. A synergistic effect of the chemo-photothermal therapy showed a moderate hyperthermia assistance (<1 W/cm(2)) and better anticancer performance over time compared with the individual treatments. We demonstrated that such PSMA-based methodology not only enables a broad range of chemical material synthesis in the kinetic control to form Au nano-octahedrons and nanotriangles using Br(-)/I(-) ions additives but also could be extended to form Au/Fe3O4@polymer nanocomposites via proton-assisted PSMA self-assembly.
Collapse
Affiliation(s)
- Chih-Chia Huang
- Department of Photonics, Center for Micro/Nano Science and Technology, and Advanced Optoelectronic Technology Center, National Cheng Kung University , 701 Tainan, Taiwan
| | - Tzu-Ming Liu
- Institute of Biomedical Engineering & Molecular Imaging Center, National Taiwan University , Taipei 106, Taiwan
| |
Collapse
|
45
|
Palvai S, More P, Mapara N, Basu S. Chimeric Nanoparticle: A Platform for Simultaneous Targeting of Phosphatidylinositol-3-Kinase Signaling and Damaging DNA in Cancer Cells. ACS APPLIED MATERIALS & INTERFACES 2015; 7:18327-35. [PMID: 26258746 DOI: 10.1021/acsami.5b04015] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/18/2023]
Abstract
Phosphatidylinositol-3-kinase (PI3K) signaling has been hijacked in different types of cancers. Hence, PI3K inhibitors have emerged as novel targeted therapeutics in cancer treatment as mono and combination therapy along with other DNA damaging drugs. However, targeting PI3K signaling with small molecules leads to the emergence of drug resistance and severe side effects to the cancer patients. To address these, we have developed a biocompatible, biodegradable cholesterol-based chimeric nanoparticle (CNP), which can simultaneously load PI103, doxorubicin, and cisplatin in a controlled ratiometric manner. Size, shape, and morphology of these CNPs were characterized by dynamic light scattering (DLS), field-emission scanning electron microscopy (FESEM), atomic force microscopy (AFM), and transmission electron microscopy (TEM). Increased amounts of PI103, doxorubicin, and cisplatin were released from CNPs through controlled and continuous manner over 120 h at pH = 5.5 compared to neutral pH. The CNPs showed much enhanced in vitro cytotoxicity in HeLa, HL60, MCF7, and MDA-MB-231 cancer cells compared to a free drug cocktail at 24 and 48 h by inducing apoptosis. Confocal laser scanning microscopy (CLSM) imaging revealed that indeed these CNPs were internalized into subcellular lysosomes through endocytosis in a time dependent mode over 6 h and retained inside for 48 h in HeLa, MDA-MB-231, and MCF7 cells. These CNPs showed their efficacy by damaging DNA and inhibiting Akt as a downstream modulator of PI3K signaling in HeLa cervical cancer cells. These CNPs have the potential to open up new directions in next-generation nanomedicine by simultaneous targeting of multiple oncogenic signaling pathways and inducing DNA damage for augmented therapeutic outcome by reducing toxic side effects and overcoming drug resistance.
Collapse
Affiliation(s)
- Sandeep Palvai
- Department of Chemistry, Indian Institute of Science Education and Research (IISER)-Pune , Pune, 411008, Maharashtra, India
| | - Piyush More
- Department of Chemistry, Indian Institute of Science Education and Research (IISER)-Pune , Pune, 411008, Maharashtra, India
| | - Nikunj Mapara
- Department of Chemistry, Indian Institute of Science Education and Research (IISER)-Pune , Pune, 411008, Maharashtra, India
| | - Sudipta Basu
- Department of Chemistry, Indian Institute of Science Education and Research (IISER)-Pune , Pune, 411008, Maharashtra, India
| |
Collapse
|
46
|
Liu F, Gou S, Chen F, Fang L, Zhao J. Study on Antitumor Platinum(II) Complexes of Chiral Diamines with Dicyclic Species as Steric Hindrance. J Med Chem 2015; 58:6368-77. [DOI: 10.1021/jm501952r] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Affiliation(s)
- Fengfan Liu
- Pharmaceutical Research Center and School of Chemistry
and Chemical Engineering, Southeast University, Campus of Jiulong Lake in Jiangning
District, Nanjing 211189, China
- Jiangsu Province Hi-Tech Key Laboratory
for Biomedical Research, Southeast University, Nanjing 211189, China
| | - Shaohua Gou
- Pharmaceutical Research Center and School of Chemistry
and Chemical Engineering, Southeast University, Campus of Jiulong Lake in Jiangning
District, Nanjing 211189, China
- Jiangsu Province Hi-Tech Key Laboratory
for Biomedical Research, Southeast University, Nanjing 211189, China
| | - Feihong Chen
- Pharmaceutical Research Center and School of Chemistry
and Chemical Engineering, Southeast University, Campus of Jiulong Lake in Jiangning
District, Nanjing 211189, China
- Jiangsu Province Hi-Tech Key Laboratory
for Biomedical Research, Southeast University, Nanjing 211189, China
| | - Lei Fang
- Pharmaceutical Research Center and School of Chemistry
and Chemical Engineering, Southeast University, Campus of Jiulong Lake in Jiangning
District, Nanjing 211189, China
- Jiangsu Province Hi-Tech Key Laboratory
for Biomedical Research, Southeast University, Nanjing 211189, China
| | - Jian Zhao
- Pharmaceutical Research Center and School of Chemistry
and Chemical Engineering, Southeast University, Campus of Jiulong Lake in Jiangning
District, Nanjing 211189, China
| |
Collapse
|
47
|
Han X, Sun J, Wang Y, He Z. Recent Advances in Platinum (IV) Complex-Based Delivery Systems to Improve Platinum (II) Anticancer Therapy. Med Res Rev 2015; 35:1268-99. [PMID: 26280923 DOI: 10.1002/med.21360] [Citation(s) in RCA: 76] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Cisplatin and its platinum (Pt) (II) derivatives play a key role in the fight against various human cancers such as testicular, ovarian, head and neck, lung tumors. However, their application in clinic is limited due to dose- dependent toxicities and acquired drug resistances, which have prompted extensive research effort toward the development of more effective Pt (II) delivery strategies. The synthesis of Pt (IV) complex is one such an area of intense research fields, which involves their in vivo conversion into active Pt (II) molecules under the reducing intracellular environment, and has demonstrated encouraging preclinical and clinical outcomes. Compared with Pt (II) complexes, Pt (IV) complexes not only exhibit an increased stability and reduced side effects, but also facilitate the intravenous-to-oral switch in cancer chemotherapy. The overview briefly analyzes statuses of Pt (II) complex that are in clinical use, and then focuses on the development of Pt (IV) complexes. Finally, recent advances in Pt (IV) complexes in combination with nanocarriers are highlighted, addressing the shortcomings of Pt (IV) complexes, such as their instability in blood and irreversibly binding to plasma proteins and nonspecific distribution, and taking advantage of passive and active targeting effect to improve Pt (II) anticancer therapy.
Collapse
Affiliation(s)
- Xiaopeng Han
- School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, Shenyang, 110016, China
| | - Jin Sun
- School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, Shenyang, 110016, China.,Municipal Key Laboratory of Biopharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, Shenyang, 110016, China
| | - Yongjun Wang
- School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, Shenyang, 110016, China
| | - Zhonggui He
- School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road, Shenyang, 110016, China
| |
Collapse
|
48
|
Massaguer A, González-Cantó A, Escribano E, Barrabés S, Artigas G, Moreno V, Marchán V. Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides. Dalton Trans 2015; 44:202-12. [PMID: 25369773 DOI: 10.1039/c4dt02710h] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Conjugates of a Pt(IV) derivative of picoplatin with monomeric (Pt-c(RGDfK), 5) and tetrameric (Pt-RAFT-{c(RGDfK)}4, 6) RGD-containing peptides were synthesized with the aim of exploiting their selectivity and high affinity for αVβ3 and αVβ5 integrins for targeted delivery of this anticancer metallodrug to tumor cells overexpressing these receptors. Solid- and solution-phase approaches in combination with click chemistry were used for the preparation of the conjugates, which were characterized by high resolution ESI MS and NMR. αVβ3 and αVβ5 integrin expression was evaluated in a broad panel of human cancer and non-malignant cells. SK-MEL-28 melanoma cells were selected based on the high expression levels of both integrins, while CAPAN-1 pancreatic cancer cells and 1BR3G fibroblasts were selected as the negative control. Internalization experiments revealed a good correlation between integrin expression and the cellular uptake of the corresponding fluorescein-labeled peptides and that the internalization capacity of the tetrameric RGD-containing peptide was considerably higher than that of the monomeric one. Cytotoxic experiments indicated that the antitumor activity of picoplatin in melanoma cells was increased by 2.6-fold when its Pt(IV) derivative was conjugated to c(RGDfK) (IC50 = 12.8 ± 2.1 μM) and by 20-fold when conjugated to RAFT-{c(RGDfK)}4 (IC50 = 1.7 ± 0.6 μM). In contrast, the cytotoxicity of the conjugates was inhibited in control cells lacking αVβ3 and αVβ5 integrin expression. Finally, cellular uptake studies by ICP-MS confirmed a good correlation between the levels of expression of integrins, intracellular platinum accumulation and antitumor activity. Indeed, accumulation and cytotoxicity were much higher in SK-MEL-28 cells than in CAPAN-1, being particularly higher in the case of the tetrameric conjugate. The overall results highlight that the great ability of RAFT-{c(RGDfK)}4 to bind to and to be internalized by integrins overexpressed in SK-MEL-28 cells results in higher accumulation of the Pt(IV) complex, leading to a high antitumor activity. These studies provide new insights into the potential of targeting αVβ3 and αVβ5 integrins with Pt(IV) anticancer pro-drugs conjugated to tumor-targeting devices based on RGD-containing peptides, particularly on how multivalency can improve both the selectivity and potency of such metallodrugs by increasing cellular accumulation in tumor tissues.
Collapse
Affiliation(s)
- Anna Massaguer
- Departament de Biologia, Universitat de Girona, Campus Montilivi, E-17071 Girona, Spain.
| | | | | | | | | | | | | |
Collapse
|
49
|
Wang Z, Ma R, Yan L, Chen X, Zhu G. Combined chemotherapy and photodynamic therapy using a nanohybrid based on layered double hydroxides to conquer cisplatin resistance. Chem Commun (Camb) 2015; 51:11587-90. [PMID: 26096645 DOI: 10.1039/c5cc04376j] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A nanohybrid is assembled by ratiometrically co-loading Pt(IV) prodrugs and photosensitizers into layered double hydroxide nanoparticles. The nanohybrid shows synergistic cell-killing effects and is significantly active against the proliferation of cisplatin-resistant human cancer cells with nanomolar IC50 values. Profound mechanistic investigations confirm its action mode of combined chemo- and photodynamic therapy.
Collapse
Affiliation(s)
- Zhigang Wang
- Department of Biology and Chemistry, City University of Hong Kong, Kowloon Tong, Hong Kong SAR.
| | | | | | | | | |
Collapse
|
50
|
Hernández-Gil J, Cobaleda-Siles M, Zabaleta A, Salassa L, Calvo J, Mareque-Rivas JC. An Iron Oxide Nanocarrier Loaded with a Pt(IV) Prodrug and Immunostimulatory dsRNA for Combining Complementary Cancer Killing Effects. Adv Healthc Mater 2015; 4:1034-42. [PMID: 25846677 DOI: 10.1002/adhm.201500080] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2015] [Revised: 03/08/2015] [Indexed: 01/10/2023]
Abstract
There is major current interest in harnessing the immune system against cancer and in developing drugs that provide complementary cancer killing mechanisms. Although the recent advent of nanoparticle-based drug delivery systems has improved the efficacy of platinum drugs for chemotherapy, one of the fundamental paradigms in their design and use is evading surveillance by the immune system to enhance anticancer efficacy. However, new studies are showing that chemotherapy can profit from actively targeting stimulation of the immune system and that suitably functionalized nanomaterials might be ideal for overcoming some key challenges in immunotherapy. Pt(IV) prodrug-modified PEGylated phospholipid micelles that encapsulate biocompatible iron oxide nanoparticles (IONPs) as a new delivery system for cisplatin are reported. The Pt(IV)-IONPs are functionalized with polyinosinic-polycytidylic acid (poly (I:C))--a double stranded RNA (dsRNA) analog widely used as an adjuvant in clinical trials of cancer immunotherapy. The Pt(IV)-IONPs and poly (I:C)--Pt(IV)-IONPs enhance by more than an order of magnitude the prodrug cytotoxicity in different tumor cells, while greatly increasing the ability of cisplatin and poly (I:C) to activate dendritic cells--the key cellular players in immunotherapy. The results suggest that these constructs hold promise for targeted chemoimmunotherapy.
Collapse
Affiliation(s)
- Javier Hernández-Gil
- Theranostic Nanomedicine Laboratory; CIC biomaGUNE; Paseo Miramón 182 20009 San Sebastián Spain
| | - Macarena Cobaleda-Siles
- Theranostic Nanomedicine Laboratory; CIC biomaGUNE; Paseo Miramón 182 20009 San Sebastián Spain
| | - Aintzane Zabaleta
- Theranostic Nanomedicine Laboratory; CIC biomaGUNE; Paseo Miramón 182 20009 San Sebastián Spain
| | - Luca Salassa
- Theranostic Nanomedicine Laboratory; CIC biomaGUNE; Paseo Miramón 182 20009 San Sebastián Spain
| | - Javier Calvo
- Theranostic Nanomedicine Laboratory; CIC biomaGUNE; Paseo Miramón 182 20009 San Sebastián Spain
| | - Juan C. Mareque-Rivas
- Theranostic Nanomedicine Laboratory; CIC biomaGUNE; Paseo Miramón 182 20009 San Sebastián Spain
- IKERBASQUE; Basque Foundation for Science; 48011 Bilbao Spain
| |
Collapse
|